Search
KB109
go.drugbank.com/drugs/DB16531ExperimentalKB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Hydrogen
go.drugbank.com/drugs/DB15127InvestigationalHydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).
Asunercept
go.drugbank.com/drugs/DB15160InvestigationalAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
PF-03654746
go.drugbank.com/drugs/DB12201InvestigationalPF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.
Pexacerfont
go.drugbank.com/drugs/DB12572InvestigationalPexacerfont has been investigated for the treatment of Alcoholism, Anxiety Disorder, Alcohol Dependence, and Alcohol-Related Disorders.
ALS-08
go.drugbank.com/drugs/DB05705ExperimentalALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Canis lupus familiaris hair
go.drugbank.com/drugs/DB10867ApprovedDomestic dog hair is used in allergenic testing.
Mixtures: Animal Allergens, UF Dog Hair-Dander Canis sppMitometh
go.drugbank.com/drugs/DB12117InvestigationalMitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor. … Mitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others
Elafin
go.drugbank.com/drugs/DB05161InvestigationalElafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or
AT-7519
go.drugbank.com/drugs/DB08142InvestigationalIt is developed by Astex for the treatment of solid tumours and haematological malignancies.